An overview of economic evaluations for drugs used in rheumatoid arthritis : Focus on tumour necrosis factor-α antagonists

Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory disease that affects approximately 0.5-1% of the adult population. The introduction of new disease-modifying antirheumatic drugs (DMARDs) such as leflunomide, anakinra and the tumour necrosis factor (TNF)-alpha antagonists (infliximab...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2005-01, Vol.65 (4), p.473-496
Hauptverfasser:	BANSBACK, Nick J, REGIER, Dean A, ARA, Roberta, BRENNAN, Alan, SHOJANIA, Kamran, ESDAILE, John M, ANIS, Aslam H, MARRA, Carlo A
Format:	Artikel
Sprache:	eng
Schlagworte:	Antirheumatic Agents - economics Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - economics Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents Cost of Illness Cost-Benefit Analysis Diseases of the osteoarticular system Drug Costs Humans Inflammatory joint diseases Medical sciences Pharmacology. Drug treatments Quality of Life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!